Back-to-School Season in Italy

As an American pediatrician who has spent a lot of time in Italy, where the pandemic began in February and the whole country was in lockdown by early March, I’m interested in how children and families in Italy are responding to the current phase of reopening schools. While the back-to-school situation varies across the United…

Details

Missing rehab due to COVID-19 increased distress in women with breast cancer

September 28, 2020 – Beyond the tragic surges in hospitalizations and deaths, the first months of the COVID-19 pandemic disrupted healthcare for people with a wide range of medical conditions – including cancer. For women recovering after breast cancer treatment, COVID-19-related interruptions in rehabilitation care led to emotional distress and other effects on health and…

Details

Freezing prostate cancer: Study shows notable outcomes with cryoablation

September 28, 2020 – A less-invasive treatment technique called hemi-gland cryoablation (HGCryo) – destroying the areas of the prostate where cancers are located by freezing them – provides a high rate of effective prostate cancer control, according to a new study published in The Journal of Urology®, Official Journal of the American Urological Association (AUA).…

Details

New MaskCountTM app allows citizen scientists to contribute to effort to contain COVID-19

INDIANAPOLIS — A new app will allow anyone to contribute real-world data to the effort to understand COVID-19. “MaskCountTM,” from Regenstrief Institute, lets users document the number of people they see wearing or not-wearing masks, all without identifying anyone. This information will be combined for display and analyzed with other COVID-19 data, such as case…

Details

Cincinnati Children’s research helps pave way for newly approved use of drug

Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children’s Hospital Medical Center, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome. Hypereosinophilic syndrome, also known as HES, is a life-threatening group of blood disorders…

Details